G37.3 Acute transverse myelitis in demyelinating disease of central nervous system

Name of the Condition

• Acute transverse myelitis in demyelinating disease of central nervous system

Summary

Acute transverse myelitis in demyelinating disease of the central nervous system (CNS) is a condition characterized by inflammation and demyelination of the spinal cord, leading to acute neurological deficits. This process disrupts nerve signal transmission, resulting in symptoms that typically develop over hours to days. The condition is associated with underlying demyelinating diseases of the CNS, which may include autoimmune or inflammatory mechanisms.

Causes

The causes of acute transverse myelitis in demyelinating disease of the CNS are linked to autoimmune responses targeting the myelin sheath of the spinal cord. Underlying demyelinating conditions, such as multiple sclerosis or neuromyelitis optica spectrum disorder, may trigger this inflammation. In some cases, infections or other inflammatory processes can contribute to the development of acute transverse myelitis.

Risk Factors

• Pre-existing demyelinating diseases (e.g., multiple sclerosis)
• Autoimmune disorders
• Viral or bacterial infections
• Exposure to certain environmental triggers
• Genetic predispositions to inflammatory conditions

Symptoms

• Sudden onset of weakness or paralysis in limbs
• Sensory disturbances (e.g., numbness, tingling, or loss of sensation)
• Bladder or bowel dysfunction
• Back pain (often localized to the affected spinal cord segment)
• Difficulty with coordination or balance
• Fatigue

Diagnosis

Diagnosis involves a combination of clinical evaluation, magnetic resonance imaging (MRI) to detect spinal cord inflammation or demyelination, and laboratory tests to rule out infections or other causes. A neurological examination assesses functional impairments, and cerebrospinal fluid analysis may be performed to identify inflammatory markers or antibodies associated with demyelinating diseases.

Treatment Options

Treatment focuses on reducing inflammation and managing symptoms. Corticosteroids are commonly used to suppress the immune response. Plasmapheresis or intravenous immunoglobulin may be considered in severe cases. Symptomatic management includes physical therapy, bladder or bowel training, and pain relief. Underlying demyelinating diseases may require long-term immunomodulatory therapy.

Prognosis and Follow-Up

Prognosis varies depending on the extent of spinal cord damage and the underlying cause. Some patients experience partial or complete recovery, while others may have persistent neurological deficits. Follow-up care includes regular neurological assessments, rehabilitation, and monitoring for relapses or progression of the underlying demyelinating disease.

Complications

• Permanent weakness or paralysis
• Chronic pain
• Bladder or bowel incontinence
• Sexual dysfunction
• Recurrent episodes of myelitis
• Psychological distress due to disability

Lifestyle & Prevention

• Engage in regular physical therapy to maintain mobility and strength.
• Manage underlying demyelinating conditions with prescribed medications.
• Avoid known triggers (e.g., infections, stress) that may exacerbate inflammation.
• Maintain a healthy lifestyle to support overall neurological health.

When to Seek Professional Help

Seek immediate medical attention if you experience sudden weakness, numbness, or sensory changes in the limbs, especially if accompanied by bladder or bowel dysfunction. Early intervention can improve outcomes and reduce the risk of permanent damage.

Tips for Medical Coders

When coding for acute transverse myelitis in demyelinating disease of the CNS, ensure documentation supports the acute nature of the myelitis and its association with a demyelinating process. Include details on clinical presentation, diagnostic findings (e.g., MRI results), and treatment to justify the code. Verify that the underlying demyelinating disease is documented separately if applicable.